about the author

Amber Tong

amber@endpointsnews.com @AmberTongPW
Amber Tong on LinkedIn

author articles

Lat­est news on Covid vac­cine OK; No­var­tis' 1 win and 1 flop; Eli Lil­ly and the Alzheimer's puz­zle; End of an era for ...

4 years ago
Weekly

Two decades af­ter Gleevec ap­proval, No­var­tis scores new CML OK for 'wild card' STAMP in­hibitor

4 years ago
R&D

Check­mate CEO hits the ex­it as Art Krieg's crew strug­gles to warm in­vestors to TLR9 strat­e­gy

4 years ago
People

Koch leads mam­moth $215M in­fu­sion in­to AI start­up boast­ing 'largest data­base' of im­mune cells

4 years ago
Financing
AI

With Covid-19 vac­cine in lim­bo, Chi­na's Fo­s­un inks $628M deal for a Pre­vnar 13 ri­val

4 years ago
Deals
China

Feds ar­rest pop­u­lar Twit­ter day trad­er over al­leged 'pump and dump' scheme

4 years ago
People

How Chi­na turned the ta­bles on bio­phar­ma's glob­al deal­mak­ing

4 years ago
China
In Focus

The biotech be­hind Glax­o­SmithK­line's PD-1 just scored a $250M cash deal for roy­al­ties

4 years ago
Deals

An­oth­er NASH play­er re­treats from bat­tered field af­ter tox­i­col­o­gy study flags po­ten­tial de­lay

4 years ago
R&D

Sanofi, Re­gen­eron gear up for new Dupix­ent fil­ing af­ter clear­ing sec­ond PhI­II for eosinophilic esophagi­tis

4 years ago
R&D
Pharma

Af­ter pass­ing on Ac­celeron, Bris­tol My­ers eyes bolt-on ac­qui­si­tion of au­toim­mune spe­cial­ist — re­port

4 years ago
Deals

So — that pig-to-hu­man trans­plant; Po­ten­tial di­a­betes cure reach­es pa­tient; Ac­cused MIT sci­en­tist lash­es back; and ...

4 years ago
Weekly

Sanofi, Re­gen­eron etch out an­oth­er PhI­II vic­to­ry for Dupix­ent, eas­ing se­vere itch and clear­ing le­sions

4 years ago
R&D
Pharma

Brid­get Martell on tak­ing Yale spin­out 'to adult­hood'; Cul­li­nan On­col­o­gy CEO an­nounces res­ig­na­tion as Bris­tol My­ers ...

4 years ago
Peer Review

Pfiz­er throws its weight be­hind LNP play­er eye­ing mR­NA treat­ments for CF, PCD

4 years ago
Financing
Cell/Gene Tx

Bris­tol My­ers pledges to sell its Ac­celeron shares as ac­tivist in­vestors cir­cle Mer­ck­'s $11.5B buy­out — re­port

4 years ago
Deals
Pharma

Ep­i­darex, Sofinno­va dou­ble down on a par­al­lel take on 3rd-gen CAR-T — aim­ing straight at ovar­i­an can­cer

4 years ago
Financing
Cell/Gene Tx

Carl June lends 'wings' to Chi­nese CAR-T start­up led by for­mer post­doc, pur­su­ing off-the-shelf ap­proach with CRISPR ...

4 years ago
People
Cell/Gene Tx

Gates Foun­da­tion pledges $120M to ramp up gener­ic sup­ply of Mer­ck­'s Covid-19 pill while ac­tivists blast Pfiz­er's ...

4 years ago
Coronavirus

Sage, Bio­gen head to FDA with $3.1B de­pres­sion drug; Sana puts down $50M to tap Beam's CRISPR tech

4 years ago
News Briefing

Sofinno­va hauls in $548M to build and scale star­tups — as Eu­ro­pean VCs step up their bio­phar­ma game

4 years ago
Financing

Omeros plunges deep­er af­ter FDA re­jects rare dis­ease drug, ask­ing for more in­for­ma­tion

4 years ago
FDA+

Small biotech says its Covid-19 vac­cine spurs more an­ti­bod­ies than As­traZeneca’s. Will sup­ply deals come now?

4 years ago
R&D
Coronavirus

Covid-19 vac­cine boost­ers earn big thumbs up, but Mod­er­na draws ire over world sup­ply; What's next for Mer­ck’s ...

4 years ago
Weekly
First page Previous page 42434445464748 Next page Last page
A service from the Financial Times